Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

Documenti analoghi

• Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
  di: Scott R. Solomon, et al.
  Pubblicazione: (2016-01-01)
• Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
  di: Scott R. Goldsmith, et al.
  Pubblicazione: (2016-11-01)
• Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide in patients with inborn errors of immunity: Experience in a reference center in Colombia
  di: Diego Medina, et al.
  Pubblicazione: (2024-12-01)
• Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation
  di: Sarah Kayser, et al.
  Pubblicazione: (2024-12-01)
• Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial
  di: Forrest L. Baker, et al.
  Pubblicazione: (2025-04-01)